

SUPPLEMENTARY MATERIAL

Patients receiving *Apis mellifera* venom

Patient	Gender	Age (years)	CV	Culprit insect	Brown**	Total IgE (UI/mL)	Baseline tryptase (µg/L)	slgE Api m (KU ^A /L)	slgE Api m 1 (KU ^A /L)	slgE Api m 10 (KU ^A /L)	slgE CCD (KU ^A /L)	REMA
#1	M	70	0	<i>Apis m</i>	2	42	6.5	2.7	2.4	0.0	0.0	1
#2	F	53	0	<i>Apis m</i>	1	4	4.3	3.1	2.2	0.07	0.0	-4
#3	M	42	0	<i>Apis m</i>	3	79	1.3	19.2	4.2	7.9	0.0	0
#4	M	61	0	<i>Apis m</i>	2	62	6.3	4.3	4.3	0.14	0.0	-2
#5	M	68	0	<i>Apis m</i>	3	174	9.1	37.6	1.7	4.4	0.7	-1
#6	M	65	0	<i>Apis m</i>	2	5	19.8	2.6	2.5	0.06	0.03	1
#7	M	39	0	<i>Apis m</i>	2	50	2.8	26.1	4.2	0.02	1.0	-1
#8	F	47	0	<i>Apis m</i>	1	262	3.7	44.9	15.3	0.8	3.9	-4
#9	M	50	1	<i>Apis m</i>	2	1197	3.3	42.6	4.5	6.2	16.3	0
#10	M	75	1	<i>Apis m</i>	1	488	6.7	60.9	22.2	8.9	8.0	-1
#11	M	34	0	<i>Apis m</i>	1	51	UK	23.3	15.3	0.22	1.10	UK
#12	M	41	0	<i>Apis m</i>	2	30	16.1	5.73	5.08	0.00	0.11	-1
#13	F	47	0	<i>Apis m</i>	1	8	3.7	5.56	2.11	0.48	0.10	-4
#14	F	72	0	<i>Apis m</i>	1	88	4.8	13.1	10.2	0.01	2.51	-4
#15	F	67	0	<i>Apis m</i>	2	38	5.4	6.95	4.66	0.00	0.14	-4
#16	M	58	0	<i>Apis m</i>	2	72	14.6	2.04	0.21	0.1	0.01	1
#17	M	27	0	<i>Apis m</i>	1	54	UK	2.88	1.86	0.85	0.03	UK
#18	F	49	0	<i>Apis m</i>	1	16	5.3	15.8	16.7	0.27	0.08	-4
#19	M	51	0	<i>Apis m</i>	1	118	1.2	6.20	1.25	0.19	0.19	-2
#20	M	59	0	UK	3	18	10.4	18.0	11.1	12.5	0.01	4

Patients receiving *Vespula* spp venom

Patient	Gender	Age (years)	CV	Culprit insect	Brown**	Total IgE (UI/mL)	Baseline tryptase (µg/L)	slgE Vespula (Vespa v) (KU ^A /L)	slgE Ves v 1 (KU ^A /L)	slgE Ves v 5 (KU ^A /L)	slgE CCD (KU ^A /L)	REMA
#21	M	16	0	<i>Vespula</i>	1	864	6.4	3.1	3.6	1.4	0,5	-2
#22	M	63	1	<i>Vespula</i>	1	412	10.2	9.0	5.6	7.6	0.0	-2
#23	F	76	0	<i>Vespula</i>	2	198	4.5	30.9	44.6	0.05	0,0	-1
#24	M	73	1	<i>Vespa v</i>	2	632	5.1	3.5 (2.6)	0.07	1.5	1.9	-2
#25	M	84	1	<i>Vespula</i>	3	84	8.0	14.3	0.1	21.8	0.0	0
#26	F	80	1	<i>Vespa v</i>	3	16	12.0	1.4 (0.5)	0.2	1.7	0.2	-1
#27	F	78	1	<i>Vespa v</i>	2	38	8.9	9.3 (2.6)	0.1	9.1	0.1	-4
#28	M	55	0	<i>Vespa v</i>	1	228	5.0	17.8 (6.5)	19.5	5.3	0.4	-2

#29	M	49	0	<i>Vespa v</i>	2	47	6.5	5.6 (1.7)	2.2	3.5	1.0	1
#30	M	72	1	<i>Vespula</i>	1	250	5.2	60.9	0.08	50.5	1.7	-2
#31	F	58	1	<i>Vespa v</i>	3	278	8.3	4.0 (9.4)	0.1	1.4	0.3	-1
#32	M	56	0	<i>Vespa v</i>	3	1118	1.9	11.6 (15.5)	10.4	3.3	4.6	4
#33	M	83	0	<i>Vespa v</i>	3	12	5.9	1.6 (0.5)	0.0	1.5	0.0	1
#34	F	63	0	<i>Vespa v</i>	1	29	8.0	4.7 (1.8)	2.0	3.3	0.2	-4
#35	M	49	1	<i>Vespula</i>	1	18	2.7	4.9	0.3	4.6	0.1	-3
#36	F	60	1	<i>Vespula</i>	1	894	2.8	32.8	28.2	14.4	2.7	-4
#37	M	58	0	<i>Vespula</i>	2	63	3.4	9.6	15.5	0.2	0.3	1
#38	F	72	1	<i>Vespula</i>	2	292	7.8	0.6	1.7	0.2	0.0	-1
#39	M	73	1	<i>Vespa v</i>	1	190	6.2	13.7 (7.6)	23.4	0.0	0.0	-2
#40	M	76	1	<i>Vespa v</i>	1	178	4.8	1.1 (0.4)	0.1	0.8	0.4	-2
#41	F	61	0	<i>Vespula</i>	2	308	2.6	3.1	0.3	2.8	0.1	-4
#42	M	50	0	<i>Vespula</i>	2	12	6.8	9.3	0.0	11.7	0.1	-1
#43	M	49	0	<i>Vespa v</i>	2	11	8.2	2.7 (0.2)	0.5	2.9	0.0	-2
#44	M	39	0	<i>Vespa v</i>	2	140	7.0	14.0 (4.9)	2.88	13.1	0.04	-2
#45	M	67	0	<i>Vespa v</i>	3	22	4.6	14.4 (2.8)	0.01	16.1	0.35	1
#46	M	70	0	<i>Vespula</i>	2	84	5.1	17.3	19.7	0.03	0.66	1
#47	M	77	0	<i>Vespa v</i>	1	84	6.1	10.8	10.7	6.36	0.00	-2
#48	M	43	0	<i>Vespa v</i>	3	482	18.2	2.19	0.03	5.09	UK	5
#49	M	47	0	<i>Vespa v</i>	1	112	5.1	8.11	1.46	5.30	0.54	-2
#50	M	42	0	<i>Vespa v</i>	2	220	5.7	10.3 (2.0)	3.52	11.8	0.46	1
#51	M	76	0	<i>Vespula</i>	2	101	7.0	29.8	11.6	28.2	UK	2
#52	F	70	0	<i>Vespa v</i>	2	56	4.9	6.91 (1.4)	1.67	5.3	0.20	-4
#53	M	44	0	<i>Vespa v</i>	3	246	7.8	28.8 (5.7)	3.38	32.8	0.15	-2
#54	F	72	0	<i>Vespa v</i>	2	92	9.9	10.2 (1.6)	1.23	16.8	0.05	-1
#55	M	49	0	<i>Vespa v</i>	3	456	10.5	32.6	0.06	66.6	1.93	1
#56	M	58	0	<i>Vespa v</i>	3	71	12.5	45.7	0.38	45.4	0.17	1
#57	F	44	0	<i>Vespa v</i>	2	592	3.2	43.3 (20.0)	21.7	20.0	1.72	-1
#58	M	34	0	<i>Vespa v</i>	2	143	5.1	0.83 (0.7)	0.02	1.15	0.01	1
#59	M	72	0	<i>Vespa v</i>	2	28	6.3	10.0 (1.7)	0.05	11.5	0.18	1
#60	M	49	0	<i>Vespa v</i>	3	242	4.2	46.1 (5.3)	0.59	>100	0.01	1
#61	F	57	0	<i>Vespula</i>	2	52	3.8	4.71	4.68	0.24	0.02	2
#62	M	53	0	UK	2	266	3.6	10.3	1.23	17.3	0.06	-2

Supplementary file. Clinical and laboratory data in patients of the study. CV: history of cardiovascular disease and/or use of beta-blockers or ACE inhibitors. REMA score (Spanish Network on Mastocytosis [8])

Patients with a systemic reaction during the up-dosing schedule are presented in red. In those patients with reaction to *Vespa velutina* when sIgE was available, it is presented within parenthesis after sIgE to *Vespula spp*